Mexico Non-alcoholic Steatohepatitis Biomarkers Market Size & Outlook

The non-alcoholic steatohepatitis biomarkers market in Mexico is expected to reach a projected revenue of US$ 39.4 million by 2030. A compound annual growth rate of 18.8% is expected of Mexico non-alcoholic steatohepatitis biomarkers market from 2022 to 2030.
Revenue, 2021 (US$M)
$8.4
Forecast, 2030 (US$M)
$39.4
CAGR, 2022 - 2030
18.8%
Report Coverage
Mexico

Mexico non-alcoholic steatohepatitis biomarkers market, 2018-2030 (US$M)

Mexico

Related Markets

Mexico non-alcoholic steatohepatitis biomarkers market highlights

  • The Mexico non-alcoholic steatohepatitis biomarkers market generated a revenue of USD 8.4 million in 2021 and is expected to reach USD 39.4 million by 2030.
  • The Mexico market is expected to grow at a CAGR of 18.8% from 2022 to 2030.
  • In terms of segment, serum biomarkers was the largest revenue generating type in 2021.
  • Hepatic Fibrosis Biomarkers is the most lucrative type segment registering the fastest growth during the forecast period.


Non-alcoholic steatohepatitis biomarkers market data book summary

Market revenue in 2021USD 8.4 million
Market revenue in 2030USD 39.4 million
Growth rate18.8% (CAGR from 2021 to 2030)
Largest segmentSerum biomarkers
Fastest growing segmentHepatic Fibrosis Biomarkers
Historical data2018 - 2020
Base year2021
Forecast period2022 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSerum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers
Key market players worldwideGenfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co


Other key industry trends

  • In terms of revenue, Mexico accounted for 1.0% of the global non-alcoholic steatohepatitis biomarkers market in 2021.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Latin America, Brazil non-alcoholic steatohepatitis biomarkers market is projected to lead the regional market in terms of revenue in 2030.
  • Argentina is the fastest growing regional market in Latin America and is projected to reach USD 27.4 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Non-alcoholic Steatohepatitis Biomarkers Market Companies

Name Profile # Employees HQ Website

Mexico non-alcoholic steatohepatitis biomarkers market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.


Serum biomarkers was the largest segment with a revenue share of 33.33% in 2021. Horizon Databook has segmented the Mexico non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.


With a prevalence rate of 42.54% among NAFLD patients, the link between NAFLD and metabolic syndrome is well-established. Mexico has a relatively high (41%) reported prevalence of metabolic syndrome. In addition to the prevalence rate of 36.1% in the adult population, Mexico is among the countries with the highest prevalence of obesity in the world.

The prevalence of NAFLD is relatively high worldwide, but Mexicans and other people of Hispanic ancestry are disproportionately affected. The importance of screening patients with metabolic syndrome for NAFLD should be emphasized in countries with high prevalence and inadequate healthcare systems to avoid complications & lessen the disease burden.

For the purpose of diagnosing, noninvasive diagnostics, such as serum biomarkers (including the Fatty Liver Index [FLI], Hepatic Steatosis Index [HSI], and SteatoTest) employed as screening techniques to identify people with NASH.

Reasons to subscribe to Mexico non-alcoholic steatohepatitis biomarkers market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Mexico non-alcoholic steatohepatitis biomarkers market databook

  • Our clientele includes a mix of non-alcoholic steatohepatitis biomarkers market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Mexico non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Mexico non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Mexico non-alcoholic steatohepatitis biomarkers market size, by type, 2018-2030 (US$M)

Mexico Non-alcoholic Steatohepatitis Biomarkers Market Outlook Share, 2021 & 2030 (US$M)

Mexico non-alcoholic steatohepatitis biomarkers market size, by type, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more